Search Results
Results found for "Université de Montréal"
- Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for ...
April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal (Strasbourg, France; CEO: Pascal Neuville; “Domain”) and Université de Montréal (Québec, Canada; “UdM
- Michel Bouvier appointed Knight of the Ordre national du Québec
Professor in the Department of Biochemistry and Molecular Medicine of the Faculty of Medicine of the Université de Montréal, is appointed Knight of the Ordre national du Québec.
- Dr. Tim De Groof - Dr. GPCR Podcast
Tim De Groof! It’s not often when you get the best of both worlds - nano-bodies and #GPCRs.
- 📰 GPCR Weekly News, April 10 to 16, 2023
Michel Bouvier received the title of Doctor Honoris Causa from the Université de Montpellier Domain Therapeutics
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
This is the essence of de-risking GPCR programs through operational excellence. your drug discovery process from a series of disconnected efforts into a seamless, predictable, and de-risked Learn to translate your program’s internal operational precision into a compelling, de-risked narrative
- From Lab Bench to Boardroom: The Unexpected Path of a Medicinal Chemist
A postdoc in Santiago de Compostela introduced her to GPCRs, and from there, things escalated quickly
- Inside Out: Mapping GPCRs from Membrane Codes to Market Moves
conversation dives deep into the tools now transforming receptor biology—and how they’re being used to de-orphanize
- Adhesion GPCR Consortium Newsletter - May 2024
Member Profile Antony Boucard Professor Centro de Investigación y de Estudios Avanzados del IPN (Cinvestav AB: Favorite Taco: Taco de suadero (pronounced swa-day-ro), fatty, with meat caramelized in its own fat
- Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools
Boston, MA and Santiago de Compostela, Spain — [June 3rd, 2025] — Dr.
- Pharmacology at Your Fingertips: Terry’s Corner Launches
GPCR consulting that cuts through the noise, designing assay cascades, setting go/no-go points, and de-risking
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris De
- Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and...
package assist in the launch of Phase 2 clinical development Metabolic disorders are a global epidemic1 MONTREAL
- Domain Therapeutics Raises $42m Series A Financing
clinical development of its best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL
- Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B ...
Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial "MONTREAL
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
Madelyn N Moore , Kelsey L Person , Abigail Alwin , Campbell Krusemark , Ezequiel Marron Fernandez de loss after a year, with no plateau INAUGURATION OF AELIS FARMA NEW LABORATORY at Institut Européen de
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
May 2022 "MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc.
- Conjugation Strategies for Probe Development
.; Henry De Villeneuve, C.; Moraillon, A.; Ozanam, F.; Gabouze, N.; Djebbar, S.
- How Fast Does a Drug Work?
Your pipeline depends on early, well-informed decisions that move promising candidates forward while de-prioritizing
- Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells
Fluorescence Microscopy validation performed in the ONCOMET laboratory (Health Research Institute of Santiago de
- From Farm Fields to GPCR Discovery, GLP-1 and GIP
Emerging direction: Treatment sequencing + guided de-escalation.
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris De
- Fluorescence Polarization in GPCR Research
L, González A, Gioé-Gallo C, Mallo-Abreu A, Brea J, Loza MI, García-Rey A, García-Mera X, Gutiérrez-de-Terán
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
De novo drug design: AI algorithms can generate new molecules with desired properties, such as binding chemical space, limiting their ability to identify truly novel chemotypes”(Thomas, Smith, O’Boyle, de
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
running early-stage programs, recognizing this decoupling early can sharpen dose optimization and de-risk
- 📰 GPCR Weekly News, March 6 to 12, 2023
Domain Therapeutics was nominated for the Trophée de l'Innovation Technologique (Technological Innovation
- Therapeutic validation of an orphan G protein‐coupled receptor
Therefore, matching a ligand to an orphan GPCRs, the process of de-orphanizing, is of great importance
- Unlocking the Future of Medicine: Advancements in GPCR Research
This week's highlight includes congrats to Omolade Otun, Chris de Graaf, Cherine Bechara, et al. for
- FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
✅ The sooner you understand what they’re optimizing for, the faster you can align your strategy to de-risk
- 🤯Mind-blowing GPCR Scoops! Discover the Latest Breakthroughs! ⦿ Nov 18 - 24, 2024
GPCR drugmaker Septerna amasses $288M in IPO Surrounded by AI bio giants, tiny startup Nabla Bio makes de
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
Learn how to transform your program from a series of disconnected efforts into a predictable, de-risked




















